This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shoji, T. Articles by Wada, H. Search for Related Content PubMed PubMed Citation Articles by Shoji, T. Articles by Wada, H. Social Bookmarking                            What's this?

Clinical Significance of p21 Expression in Non–Small-Cell Lung Cancer

From the Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Kyoto, Japan.

Address reprint requests to Hiromi Wada, MD, Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Shogoin-kawahara-cho 54, Sakyo-ku, Kyoto 606-8397, Japan; email: wadah{at}kuhp.kyoto-u.ac.jp

PURPOSE: The clinical significance of p21 expression remains unclear, whereas many experimental studies have demonstrated that p21, the product of the WAF1/CIP1/SDI1 gene, plays an important role in regulation of the cell cycle as an inhibitor of cyclin-dependent kinases. The purpose of this study was to clarify the clinical significance in resected non–small-cell lung cancer (NSCLC).

PATIENTS AND METHODS: A total of 233 consecutive patients with completely resected pathologic stage I to IIIA NSCLC were retrospectively reviewed. Expression of p21 and the status of p53 were examined immunohistochemically. Proliferative activity was also evaluated immunohistochemically. The incidence of apoptotic cell death was evaluated by terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate-biotin nick end-labeling staining.

RESULTS: Expression of p21 was positive in 120 patients (51.5%). The 5-year survival rate of p21-positive patients was 73.8%, significantly higher than that of p21-negative patients (60.7%; P = .006). Aberrant expression of p53 was positive in 98 patients (42.1%). When combined with p53 status, the prognostic value of p21 status was enhanced: the 5-year survival rate of p21-positive and p53-negative patients was 80.7%, markedly higher than that of p21-negative and p53-positive patients (50.0% for both; P = .001). Multivariate analysis confirmed that positive expression of p21 was a significant factor for predicting a favorable prognosis. There was no significant correlation between p21 expression and p53 status, proliferative activity, or incidence of apoptosis.

CONCLUSION: p21 expression was shown to be an independent prognostic factor in NSCLC.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Tanaka, K. S. Suh, A. M. Lo, and L. M. De Luca p21WAF1/CIP1 Is a Common Transcriptional Target of Retinoid Receptors: PLEIOTROPIC REGULATORY MECHANISM THROUGH RETINOIC ACID RECEPTOR (RAR)/RETINOID X RECEPTOR (RXR) HETERODIMER AND RXR/RXR HOMODIMER J. Biol. Chem., October 12, 2007; 282(41): 29987 - 29997. [Abstract] [Full Text] [PDF]

				C-Q Zhu, W Shih, C-H Ling, and M-S Tsao Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J. Clin. Pathol., August 1, 2006; 59(8): 790 - 800. [Abstract] [Full Text] [PDF]

				A. L. Gartel Is p21 an oncogene? Mol. Cancer Ther., June 1, 2006; 5(6): 1385 - 1386. [Full Text] [PDF]

				V Esposito, A Baldi, A De Luca, G Tonini, B Vincenzi, D Santini, P Persichetti, A Mancini, G Citro, F Baldi, et al. Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer J. Clin. Pathol., July 1, 2005; 58(7): 734 - 739. [Abstract] [Full Text] [PDF]

				S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986. [Abstract] [Full Text] [PDF]

				S. Han, N. Sidell, P. B. Fisher, and J. Roman Up-regulation of p21 Gene Expression by Peroxisome Proliferator-Activated Receptor {gamma} in Human Lung Carcinoma Cells Clin. Cancer Res., March 15, 2004; 10(6): 1911 - 1919. [Abstract] [Full Text] [PDF]

				V Esposito, A Baldi, G Tonini, B Vincenzi, M Santini, V Ambrogi, T C Mineo, P Persichetti, G Liuzzi, V Montesarchio, et al. Analysis of cell cycle regulator proteins in non-small cell lung cancer J. Clin. Pathol., January 1, 2004; 57(1): 58 - 63. [Abstract] [Full Text] [PDF]

				H. Swede, Y. Dong, M. Reid, J. Marshall, and C. Ip Cell Cycle Arrest Biomarkers in Human Lung Cancer Cells After Treatment with Selenium in Culture Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1248 - 1252. [Abstract] [Full Text]